Recruitment and participant baseline characteristics in the dialysis outcomes in those aged 65 years or older study

Table 2 Assessing possibility of subcohort effect in accelerated prospective design

	Predialysis (n = 56)		Incident (< 1 year) (n = 50)		Prevalent (1–3 years) (n = 57)		Prevalent (> 3 years) (n = 62)		p value
	n	%	n	%	n	%	n	%
Gender
Male	37	66.1	33	66.0	35	61.4	39	62.9
Female	19	33.9	17	34.0	22	38.6	23	37.1	0.94
Age group
65–69	20	35.7	20	40.0	21	36.8	26	41.9
70–74	11	19.6	16	32.0	15	26.3	22	35.5
75–79	13	23.2	6	12.0	16	28.1	10	16.1	0.13
80+	12	21.4	8	16.0	5	8.8	4	6.5
Ethnicity (self reported)
European	30	53.6	19	38.0	23	40.4	24	38.7
Māori	10	17.9	10	20.0	18	31.6	12	19.4
Pacific	6	10.7	17	34.0	10	17.5	19	30.6	0.06
Other	10	17.9	4	8.0	6	10.5	7	11.3
Comorbidities^a
Cardiovascular disease	36	64.3	33	66.0	38	66.7	44	71.0	0.88
Cerebrovascular disease	4	7.1	3	6.0	5	8.8	5	8.1	0.97
Peripheral vascular disease	13	23.2	7	14.0	11	19.3	14	22.6	0.63
Diabetes mellitus	27	48.2	29	58.0	32	56.1	32	51.6	0.74
Respiratory disease	16	28.6	10	20.0	9	15.8	14	22.6	0.43
cancer (other than skin cancer)	8	14.3	11	22.0	8	14.0	11	17.7	0.67
Musculoskeletal	18	32.1	14	28.0	14	24.6	22	35.5	0.60
Other	36	64.3	30	60.0	37	64.9	37	59.7	0.91
Comorbidity count
0 to 2	24	42.9	23	46.0	29	50.9	28	45.2
3 to 6	32	57.1	27	54.0	28	49.1	34	54.8	0.85
Cause of ESKD
Glomerulonephritis	8	14.3	9	18.0	7	12.3	14	22.6
Hypertension	10	17.9	7	14.0	12	21.1	9	14.5
Polycystic kidney	2	3.6	1	2.0	4	7.0	5	8.1
Diabetes mellitus	20	35.7	22	44.0	27	47.4	23	37.1	0.55
Other	16	28.6	11	22.0	7	12.3	11	17.7